Tech Company Financing Transactions

Circle Pharma Funding Round

Circle Pharma, operating out of San Francisco, raised $45 million from The Column Group, Berkeley Catalyst Fund and Lifeforce Ventures.

Transaction Overview

Company Name
Circle Pharma
Announced On
3/18/2020
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors

The Column Group (Lead Investor) (Peter Svennilson)

Berkeley Catalyst Fund

Lifeforce Ventures

Nextech Invest (Thilo Schroeder)

ShangPharma Investment Group (Walter Moos)

Proceeds Purpose
Proceeds from the investment will be used to advance Circle's work to develop inhibitors of Cyclin A and Cyclin E, and to expand the company's pipeline.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd. LGL 3rd Floor
San Francisco, CA 94080
USA
Phone
(650) 825-4099
Website
www.circlepharma.com
Email Address
[email protected]
Overview
We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function).
Profile
Circle Pharma LinkedIn Company Profile
Social Media
Circle Pharma Company Twitter Account
Company News
Circle Pharma News
Facebook
Circle Pharma on Facebook
YouTube
Circle Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Earp
  David Earp LinkedIn Profile  David Earp Twitter Account  David Earp News  David Earp on Facebook
Chief Scientific Officer
Rajinder Singh
  Rajinder Singh LinkedIn Profile  Rajinder Singh Twitter Account  Rajinder Singh News  Rajinder Singh on Facebook
Co-Founder
Matthew Jacobson
  Matthew Jacobson LinkedIn Profile  Matthew Jacobson Twitter Account  Matthew Jacobson News  Matthew Jacobson on Facebook
Co-Founder
Scott Lokey
  Scott Lokey LinkedIn Profile  Scott Lokey Twitter Account  Scott Lokey News  Scott Lokey on Facebook
Vice President
James Aggen
  James Aggen LinkedIn Profile  James Aggen Twitter Account  James Aggen News  James Aggen on Facebook
VP - Operations
Amy Cowgill
  Amy Cowgill LinkedIn Profile  Amy Cowgill Twitter Account  Amy Cowgill News  Amy Cowgill on Facebook
VP - R & D
Pablo Garcia
  Pablo Garcia LinkedIn Profile  Pablo Garcia Twitter Account  Pablo Garcia News  Pablo Garcia on Facebook
VP - R & D
Constantine Kreatsoulas
  Constantine Kreatsoulas LinkedIn Profile  Constantine Kreatsoulas Twitter Account  Constantine Kreatsoulas News  Constantine Kreatsoulas on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/17/2020: Tempus venture capital transaction
Next: 3/18/2020: Axis Security venture capital transaction

 

Share this article

 

Where The Data Comes From

We record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.